Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focusing on creating value for people living with neurology and immunology conditions.
Celebrating 90 years of innovation #UCB90
Twitter Feed
-
With operations in 40 countries and over 7,500 people, we focus on developing patient-centered treatments in the areas of neurology and immunology. #UCB90 #PatientsFirst 📈 Find out our key facts and figures here: https://t.co/D9x9Z8ok98
— UCB News (@ucb_news) 20.08.2018 -
We are working with patients and policymakers to help prevent fragility fractures https://t.co/kCTCwNTGzm #osteoporosis https://t.co/0JCK6xZJpP
— UCB News (@ucb_news) 20.08.2018 -
Find out the impact that #Osteoporosis can have on day-to-day life here: https://t.co/LLBsKLJJe0 https://t.co/d9CikM6Zms
— UCB News (@ucb_news) 20.08.2018
Highlights
UCB Ventures, a strategic corporate venture fund established in 2017 to further strengthen UCB’s ability to create value from novel insights and technologies that can transform the lives of patients suffering from severe diseases, has announced its first direct investment.
